



SAVARA

Pharmaorigin ApS

CVR 29178291

Annual Report

In accordance with
ÅRL Danish Financial Statement Act

2016

The Annual Accounts has been presented and approved at the generally assembly ³¹/₅ 2017

Martin Christiansen

Table of Content

1	Management's Report	3
2	Independent Auditors Report	4-5
3	Managements Review	6-7
4	Profit and Loss Account	8
5	Balance sheet at 31 December 2016	9-10
6	Changes in Equity	11
7	Notes to the Accounts	12-22



MANAGEMENT'S REPORT

Statement of the Board of Directors and Executive Board

The Executive Management has today presented the financial statements of Pharmaorigin ApS, CVR 29178291, for the period 1 January to 31 December 2016.

The financial statements have been prepared in accordance with The Danish Financial Statement Act. In my opinion, the financial statements give a true and fair view of the company's assets, liabilities and financial position at 31 December 2016 and of the result of the operations for the period 1 January to 31 December 2016.

I am of the opinion that the Management's Review includes a fair description of the issues dealt with.

The annual report is recommended for approval at the general meeting.

Hørsholm, 31 May 2017

PHARMAORIGIN APS



Robert Neville
I am approving this document

Robert Neville
CEO

INDEPENDENT AUDITORS REPORT

To the shareholders of Pharmaorigin ApS

Opinion

We have audited the annual accounts of Pharmaorigin ApS for the financial year 1 January to 31 December 2016, which comprise accounting policies used, profit and loss account, balance sheet and notes. The annual accounts are prepared in accordance with the Danish Financial Statements Act.

In our opinion, the annual accounts give a true and fair view of the company's assets, liabilities and financial position at 31 December 2016 and of the results of the company's operations for the financial year 1 January to 31 December 2016 in accordance with the Danish Financial Statements Act.

Basis for opinion

We conducted our audit in accordance with international standards on auditing and the additional requirements applicable in Denmark. Our responsibilities under those standards and requirements are further described in the below section "Auditor's responsibilities for the audit of the annual accounts". We are independent of the company in accordance with international ethics standards for accountants (IESBA's Code of Ethics) and the additional requirements applicable in Denmark, and we have fulfilled our other ethical responsibilities in accordance with these standards and requirements. We believe that the audit evidence obtained is sufficient and appropriate to provide a basis for our opinion.

The management's responsibilities for the annual accounts

The management is responsible for the preparation of annual accounts that give a true and fair view in accordance with the Danish Financial Statements Act. The management is also responsible for such internal control as the management determines is necessary to enable the preparation of annual accounts that are free from material misstatement, whether due to fraud or error.

In preparing the annual accounts, the management is responsible for evaluating the company's ability to continue as a going concern, and, when relevant, disclosing matters related to going concern and using the going concern basis of accounting when preparing the annual accounts, unless the management either intends to liquidate the company or to cease operations, or if it has no realistic alternative but to do so.

Auditor's responsibilities for the audit of the annual accounts

Our objectives are to obtain reasonable assurance about whether the annual accounts as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report including an opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with international standards on auditing and the additional requirements applicable in Denmark will always detect a material misstatement when it exists. Misstatements may arise due to fraud or error and may be considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions made by users on the basis of the annual accounts

As part of an audit conducted in accordance with international standards on auditing and the additional requirements applicable in Denmark, we exercise professional evaluations and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement in the annual accounts, whether due to fraud or error, design and perform audit procedures in response to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk

of not detecting a material misstatement resulting from fraud is higher than the risk of not detecting a misstatement resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

- Obtain an understanding of the internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the company's internal control.
- Evaluate the appropriateness of accounting policies used by the management and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of the management's preparation of the annual accounts being based on the going concern principle and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may raise significant doubt about the company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the annual accounts or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and contents of the annual accounts, including the disclosures in the notes, and whether the annual accounts reflect the underlying transactions and events in a manner that gives a true and fair view.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in the internal control that we identify during our audit.

Statement on the management's review

The management is responsible for the management's review.

Our opinion on the annual accounts does not cover the management's review, and we do not express any kind of assurance opinion on the management's review.

In connection with our audit of the annual accounts, our responsibility is to read the management's review and in that connection, consider whether the management's review is materially inconsistent with the annual accounts or our knowledge obtained during the audit, or whether it otherwise appears to contain material misstatement.

Furthermore, it is our responsibility to consider whether the management's review provides the information required under the Danish Financial Statements Act.

Based on the work we have performed, we believe that the management's review is in accordance with the annual accounts and that it has been prepared in accordance with the requirements of the Danish Financial Statement Acts. We did not find any material misstatement in the management's review.

Copenhagen, 31 May 2017

Grant Thornton

Statsautoriseret Revisionspartnerselskab

Company reg. no. 34 20 99 36



Ulrik Bloch-Sørensen

State Authorised Public Accountant



Martin Bomholtz

State Authorised Public Accountant

MANAGEMENT REVIEW

MAIN ACTIVITY

Pharmaorigin ApS is a subsidiary of Savara ApS and in group with Savara Inc., a U.S.-based emerging pharmaceutical development company. The company is focused on advancing inhalation therapies for the treatment of patients with rare pulmonary conditions. In Pharmaorigin ApS, the treatment is centered around Molgradex, inhaled nebulized GM-CSF to treat Pulmonary Alveolar Proteinosis (PAP).

EXTRAORDINARY EVENTS

Savara Inc. (USA) has as of 15 July 2016 acquired the two subsidiaries Drugrecure ApS and Pharmaorigin ApS from Serendex A/S, and will seek to proceed the development projects included in the two companies. Savara ApS has as of the same date been established in order to continue the operation in Denmark including the two subsidiaries.

No other extraordinary events have occurred in 2016.

ESTIMATES AND JUDGEMENTS

The preparation of the financial statements requires the making of estimates and judgments that affect the reporting of assets, liabilities and expenses. The estimates and judgments are reviewed on an ongoing basis. Estimates and judgments are based on historical results and on various other assumptions, which Pharmaorigin believes to be reasonable under the circumstances. However, the actual results may differ significantly from the estimates. We believe that the accounting policies relating to development costs and deferred tax involve estimates or judgments by management that could materially affect the reported financial position and results.

Development costs

Pharmaorigin is confident it will obtain approval of its pipeline products, as the products are based on an existing approved drug, and hold the evidence to support this. Pharmaorigin is confident, that it will acquire the necessary resources to either sell or complete the development. Thus, management judge that the technical feasibility criterion for recognition of development costs as non-current intangible assets is met. Management has reviewed the development cost and has not identified any need for impairment.

DEVELOPMENT AND EXPECTATIONS

Pharmaorigin ApS reached a net loss of DKK -1.7 million in 2016, and holds total assets of DKK 5.4 million, equity of DKK 5.4 million and liabilities of DKK 0 as of 31 December 2016.

Pharmaorigin intends to license its products to pharmaceutical companies and thereby derive income from a combination of fixed payments and ongoing royalty income. Until Pharmaorigin has established such a license agreement, Pharmaorigin will be a capital-consuming company due to investments in drug development and in further strengthening of the pipeline. Therefore, it is vital that the company always has sufficient financial resources. Pharmaorigin does not expect commercial revenue until the fiscal year of 2019.

Based on a letter of support from the parent company Savara Inc, Pharmaorigin ApS has a satisfactory funding assurance until the end of 2017 to continue the ongoing clinical trials related to the Molgradex® project hence, the annual report for 2016 has been prepared for on-going business.

Profit and Loss Account

for the period 1 January 2016 - 31 December 2016

DKK thousand	Notes	2016	2015
External expenses		(1.713)	(179)
Operating profit/loss (-)		(1.713)	(179)
Net financials		-	-
Profit/loss (-) before tax		(1.713)	(179)
Tax expenses	2	-	44
Net profit/loss (-)		(1.713)	(135)
DISTRIBUTION OF NET RESULT			
Net profit/loss (-)		(1.713)	(135)
Suggestion of distribution			
Transferred to retained earnings		(1.713)	(135)
		(1.713)	(135)

Balance Sheet

AT 31 DECEMBER 2016

ASSETS

DKK thousand	Notes	2016	2015
FIXED ASSETS			
Fixed intangible assets			
Development projects	3	4.336	5.857
Total fixed assets		4.336	5.857
CURRENT ASSETS			
Receivables			
Tax receivables	2	-	1.096
Intercompany receivables		1.096	4
Total receivables		1.096	1.100
Total current assets		1.096	1.100
Total assets		5.432	6.957

Balance Sheet

AT 31 DECEMBER 2016

EQUITY AND LIABILITIES

DKK thousand	Notes	2016	2015
Equity			
Share capital		246	246
Statutory Reserves		23	-
Retained earnings		5.163	3.929
Total equity		5.432	4.175
Liabilities			
Intercompany balance		-	2.782
Total current liabilities		-	2.782
Total liabilities		-	2.782
Total equity and liabilities		5.432	6.957

Changes in equity

DKK thousand	Notes	Share Capital	Retained Earnings	Statutory Reserves	Total
Equity at 1 januar 2016		246	3.929	-	4.175
Profit/loss (-)		-	(1.713)	-	(1.713)
Statutory transfer of retained earnings	-	-	(23)	23	-
Debt redemption		-	2.970	-	2.970
Equity at 31 December 2016		246	5.163	23	5.432

Notes

DKK thousand

1. CAPITAL RESOURCES

Pharmaorigin intends to license its products to pharmaceutical companies and thereby derive income from a combination of fixed payments and ongoing royalty income. Until Pharmaorigin has established such a license agreement, Pharmaorigin will be a capital-consuming company due to investments in drug development and in further strengthening of the pipeline. Therefore, it is vital that the company always has sufficient financial resources. Pharmaorigin does not expect commercial revenue until the fiscal year of 2019.

Based on a letter of support from the parent company Savara Inc, Pharmaorigin ApS has a satisfactory funding assurance until the end of 2017 to continue the ongoing clinical trials related to the Molgradex® project hence, the annual report for 2016 has been prepared for on-going business.

Notes

DKK thousand

2. Tax expenses

	2016	2015
Calculated income tax for the period	-	-
Deferred tax for the year	-	(44)
Total tax expense	-	(44)

The company's tax loss carried forward has not been recognised in the balance sheet.

Potential tax reimbursements deriving from tax loss utilisation by the group joint taxation, which the company was a member of until 15 July 2016, has not been recognised, as the group has not prepared the tax computation at 31 May 2017.

3. Development projects

	2016	2015
Costs at the beginning of the year	5.857	4.403
Additions in the period	23	1.454
Disposals in the period	-	-
Costs end of period	5.880	5.857
Depreciation and writedown at the beginning of the year	-	-
Depreciation and writedown in period	1.544	-
Depreciation and writedown end of period	1.544	-
Book value end of period	4.336	5.857

All capitalised development costs are related to development work in progress.

4. Pledged assets and securities

Pharmaorigin ApS has no pledged assets nor securities as of 31 December 2016.

5. Contractual obligations and pending litigations

Pharmaorigin ApS has no contractual obligations nor pending litigations as of 31 December 2016.

6. Related-party transactions

Related parties comprise Savara Inc (USA), Savara ApS and Drugrecure ApS. In accordance with agreement with parent company, the intercompany cash balance provided, is free of interest.

Notes

DKK thousand

7. SIGNIFICANT EVENTS OCCURRING AFTER THE BALANCE SHEET DATE

The ultimate parent company to Pharmaorigin ApS, Savara Inc (Texas/USA) became a public traded company on the NASDAQ Stock Exchange as of 28 April 2017.

No other significant events have occurred subsequent to the balance sheet date that are considered to have a material influence in the evaluation of the 2016 report.

8. RELATED-PARTY TRANSACTIONS

Related parties comprise the parent company - Savara ApS and Drugrecure ApS. In accordance with agreement with parent company, the intercompany cash balance provided, is free of interest.

9. ACCOUNTING POLICIES

Accounting policies applied in the preparation of the financial statements are set out below.

New standards and interpretations

In 2016, Pharmaorigin has adopted all new and revised standards and interpretations relevant for Pharmaorigin that are applicable for accounting periods beginning 1 January 2016. Pharmaorigin assessed that revised standards and interpretations did not have a material impact on Pharmaorigin, or they were not relevant. Amended and new standards that have been published and defined as mandatory for accounting periods beginning 1 January 2017 or later have not yet been implemented.

Basis of preparation

The Annual Report has been prepared in accordance with The Danish Financial Statements Act. for class B companies. Pharmaorigin has a satisfactory funding assurance for 2017 - thus, the annual report for 2016 has been prepared for on-going business. The financial statements are presented in DKK, reflecting the company's functional currency.

Recognition and measurement in general

The net revenue is recognised in the profit and loss account if delivery and risk transfer to the buyer have taken place before the end of the year, and if the income can be determined reliably and is expected to be received. The net revenue is recognised exclusive of VAT and taxes and with the deduction of any discounts granted in connection with the sale. Recognition of value adjustments of assets and liabilities are recognised in the profit and loss account upon financial assessment.

All costs – including depreciation, amortisation, write-down, provisions, and reversals, which are due to changes in estimated amounts previously recognised in the profit and loss account – are recognised in the profit and loss account. Assets are recognised in the balance sheet when the company is liable to achieve future, financial benefits and the value of the asset can be measured reliably. Liabilities are recognised in the balance sheet when the company is liable to lose future, financial benefits and the value of the liability can be measured reliably.

Translation of foreign currency

Operational transactions in foreign currency are translated by using the exchange rate at cost basis upon bank transaction. Differences in the rate of exchange arising between the rate at the date of transaction and the rate at the date of payment are recognised in the profit and loss account as an item under net financials. Debtors, creditors, and other monetary items in foreign currency – not settled at the date of the balance sheet – are translated by using the period closing rate held by The Danish Central Bank. The difference between the closing rate and the rate at the time of establishment of the receivable or the payable is recognised in the profit and loss account under financial income and financial costs. Fixed assets and other non-monetary assets acquired in foreign currency and which are not considered to be investment assets purchased in foreign currencies are measured at the exchange rate on the transaction date.

INCOME STATEMENT

External expenses

External expenses comprise all external costs including development costs, which are not directly attributable to the Company's development of new products (capitalised costs). External expenses include depreciation and write-downs.

Net Financials

Net financials include interest income, interest expenses on loans, and realized and unrealized exchange rate gains and losses. Net financials are recognised in the profit and loss account with the amounts concerning the financial year.

Tax

Tax comprises the current tax for the year and the changes in deferred tax. Tax costs are recognised in the profit and loss account with the amounts concerning the fiscal year with the share referring to entries in the equity subsequently deferred tax asset.

BALANCE SHEET ITEMS

Fixed assets

Intangible fixed assets comprise development projects, patents, and licenses. Development costs comprise costs directly and indirectly attributable to development of new products from which the Company expects a future economic benefit.

All other development costs are recognised as costs in the profit and loss accounts.

Capitalised development costs are measured at cost with deduction of accrued amortisations or at the recoverable value, if this is lower.

The carrying amounts of intangible assets carried at cost or amortized cost are tested annually to determine whether there are indications of any impairment in excess of that expressed in normal amortisation. If that is the case, the asset is written down to the recoverable amount, which is the higher value of the net sales price and the capitalised value. Impairment losses on intangible assets are recognised under the same line item as amortisation of the assets.

For development projects in progress, the recoverable amount is assessed annually, regardless of whether any indications of impairment have been found.

After completion of the development work, capitalised development costs are amortized on a straight-line basis over the estimated financial useful life.

Profit and loss from the realization of development projects, patents, and licenses are measured as the difference between the sales price with deduction of sales costs and the book value at the time of the sale.

Write-down of assets

The book values of intangible as well as tangible fixed assets are subject to annual write-down assessment in order to disclose any indications of impairment beyond those expressed by amortisation and depreciation respectively.

If indications of impairment are disclosed, impairment tests are carried out for each individual asset or group of assets respectively. Write-down takes place to the recoverable amount, if this value is lower than the book value.

The recoverable value is equal to the value of the net selling price or the value in use, whichever is higher. The value in use is determined as the present value of the expected net income deriving from the use of the asset or the group of assets. Any loss based on the write-down test is recognised in the profit and loss account under depreciation.

Tax

Corporate tax (less than 12 months) are recognised in the balance sheet reflecting the tax credit reimbursement installment by the Danish government - receivable in November 2017.

Deferred tax is measured on the basis of all temporary differences in assets and liabilities with a balance sheet focus. Deferred tax is measured based on the tax rules and tax rates applying under the legislation on the balance sheet date and prevailing when the deferred tax is expected to be released as corporate tax.

The current tax rate is 22%.

Current liabilities

Current liabilities are measured at amortized costs, which usually corresponds to the nominal value.